Company news
Omeros Corporation news in 2022
Omeros Corporation's news releases, calls and decks from 2022, newest first.
Omeros Corporation Reports Third Quarter 2022 Financial Results
November 8, 2022
Omeros Corporation Receives Decision from FDA on Formal Dispute Resolution Request for Narsoplimab
November 7, 2022
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2022
November 3, 2022
Omeros Corporation Announces Royalty Monetization Transaction with DRI Healthcare Trust
October 2, 2022
Omeros Corporation Reports Narsoplimab Treatment Results in Critically Ill COVID-19 Patients in I-SPY COVID Trial
September 14, 2022
Omeros Corporation Receives Interim Response from FDA on Formal Dispute Resolution Request for Narsoplimab
August 16, 2022
Omeros Corporation Reports Second Quarter 2022 Financial Results
August 8, 2022
Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2022
August 3, 2022
FDA Grants Orphan Drug Designation to Omeros’ MASP-3 Inhibitor OMS906 for Treatment of Paroxysmal Nocturnal Hemoglobinuria
July 28, 2022
Omeros Corporation Reports First Quarter 2022 Financial Results
May 9, 2022
Omeros Corporation to Announce First Quarter Financial Results on May 10, 2022
May 3, 2022
Omeros Announces Journal of Clinical Oncology Publication Detailing Pivotal Trial Results for Narsoplimab in HSCT-TMA
April 19, 2022
Omeros Corporation Reports Fourth Quarter and Year-End 2021 Financial Results
February 28, 2022
Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 1, 2022
February 23, 2022
Omeros Confirms Submission of Response to FDA Regarding the BLA for Narsoplimab in the Treatment of HSCT-TMA
January 18, 2022